Royal Dutch Shell said it would import products from around the region to replace output from its Clyde refinery in Australia, which it plans to convert into a fuel terminal in 2013.
It intends to continue supplying all its existing customers after the plant stops refining, Shell vice-president Andrew Smith told reporters.
Smith said the proposal had nothing to do with the Australian government's proposed carbon tax.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
